Extended Endocrine Therapy: Is 5 Years Enough? - Wikidata - wikimedia - TriplyDB

Extended Endocrine Therapy: Is 5 Years Enough?

Extended Endocrine Therapy: Is 5 Years Enough?

http://www.wikidata.org/entity/Q38934318

about

Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.

P2860

Q48125765-A70660D3-D50D-48D7-91A0-0A4959DFF63C

P2860

Extended Endocrine Therapy: Is 5 Years Enough?

http://www.wikidata.org/entity/Q38934318

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Extended Endocrine Therapy: Is 5 Years Enough?

@en

type

label

Extended Endocrine Therapy: Is 5 Years Enough?

@en

prefLabel

Extended Endocrine Therapy: Is 5 Years Enough?

@en

P1433

Q38934318-DD77D1E5-F1F6-4EB1-A027-31B4060E7533

P1476

Q38934318-505BB691-0274-4DF4-B567-AE60C33784F6

P2093

Q38934318-E5BF5D47-743A-456C-8852-69A9F72C6FE6

Q38934318-FA7CE962-2CE8-4091-96A2-AB45151DC4E8

P2860

Q38934318-06942E17-2AFB-4DF4-BF39-8DFB3E3C030A

Q38934318-46DA780D-1961-4D78-9EE4-8B3299A76433

Q38934318-4F099F01-D829-4284-BD6C-AABF5BE4752B

Q38934318-693B2C4C-895B-4D90-9DFD-A65C07D1690E

Q38934318-76E65AE8-C560-406A-A85D-3CF91328A3B1

Q38934318-7B276CB3-1AA0-416F-AE3D-870744E4E0D5

Q38934318-7F8B2C1C-7971-4D88-8362-2EA341003963

Q38934318-8D7725CE-28BD-404B-A967-3B4BD6B16BCC

Q38934318-94F1A42A-7211-4436-B0D9-3B201A6EA899

Q38934318-9B5A7828-DA28-4242-AE83-D046A40E5AE3

P2888

Q38934318-2F3C9367-35C0-454E-A6CC-585BFD571C00

P304

Q38934318-05693B69-A736-4491-840E-6049A939784A

P31

Q38934318-D2815339-194C-426B-ACB3-E26E21E2CA17

P356

Q38934318-FD14C1AE-6CAF-4C13-ABAF-5C6027D321EE

P433

Q38934318-457497FA-5D91-4CC9-8C0C-953FA25E2E1C

P478

Q38934318-651AC9B9-3338-4503-8897-33DAE289A7ED

P577

Q38934318-265BA19D-6D8C-470C-8339-955AECC5DF89

P6179

Q38934318-8C6705E7-CC96-442C-85F0-1C59878761C9

P698

Q38934318-3CC747C9-935C-420C-BD9E-47367EBA6A31

P356

S11912-017-0576-7

P1433

Current Oncology Reports

P1476

Extended Endocrine Therapy: Is 5 Years Enough?

@en

P2093

Manali A Bhave

http://www.w3.org/2001/XMLSchema#string

N Lynn Henry

http://www.w3.org/2001/XMLSchema#string

P2860

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Adjuvant ovarian suppression in premenopausal breast cancer.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.

Letrozole in the extended adjuvant setting: MA.17

P2888

s11912-017-0576-7

P304

16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-017-0576-7

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084033422

http://www.w3.org/2001/XMLSchema#string

P698

28251491

http://www.w3.org/2001/XMLSchema#string